Patients should contact their GP or diabetes specialist nurse if they experience: Severe or persistent vomiting that prevents adequate fluid or food intake, as this increases the risk of dehydration and hypoglycaemia Severe abdominal pain , particularly if constant or radiating to the back, which could indicate pancreatitisa rare but serious adverse effect of GLP-1 receptor agonists Sudden pain in the right upper abdomen, fever or jaundice , which may indicate gallbladder problems (cholelithiasis or cholecystitis) Blood in stools or black, tarry stools Unexplained weight loss beyond what is expected from the medication's therapeutic effect Signs of dehydration , including reduced urine output, dizziness, or confusion Persistent diarrhoea lasting more than a few days Symptoms that significantly impair quality of life or prevent adherence to the medication regimen Pancreatitis is a particular concern with semaglutide, though it remains uncommon

It is true, the number of cancer deaths is increasing, but yet, individual death rates are falling (1)
AOD-9604 works through fat metabolism, not appetite suppression like GLP-1 medications
The peptide continues gaining visibility in discussions involving relaxation-associated signaling and neuroendocrine regulation pathways
Interestingly, these effects were found to not be simply regulated through the control of the levels of insulin (123)
It is also important to work with a healthcare provider who provides continued monitoring and support